CompletedNCT01134055
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
PHASE2 · 510 planned enrolment
- Countries listed
- 9
- Registry update
- January 8, 2018
immortal.lifeTrial registrations containing the exact intervention label pazopanib eye drops.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE2 · 510 planned enrolment
PHASE2 · 19 planned enrolment